Parapertussis and pertussis: Differences and similarities in incidence, clinical course, and antibody responses

International Journal of Infectious Diseases

Volumn 3, Issue 3, 1999, Pages 140-146

  Bergfors, Elisabet ^a,b   Trollfors, Birger ^a   Taranger, John ^a   Lagergård, Teresa ^a   Sundh, Valter ^a   Zackrisson, Gunilla ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Goteborg Pertussis Vaccine Trial   (Sweden)

Author keywords

Filamentous hemagglutinin (FHA); Incidence; Parapertussis; Pertactin; Pertussis; Pertussis toxin

Indexed keywords

BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HEMAGGLUTININ; IMMUNOGLOBULIN G; PERTUSSIS VACCINE; PLACEBO;

ANTIBODY RESPONSE; ARTICLE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; SWEDEN; VACCINATION; VOMITING;

EID: 0032841169     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(99)90035-8     Document Type: Article

References (25)

1. Lautrop H. Epidemics of parapertussis. 20 years'observation in Denmark. Lancet 1971; i:1195-1198.
2. Heininger U, Stehr K. Schmitt-Grohe S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13:306-309.
3. Mastrantonio P, Stefanelli P, Giuliano M, et al. Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol 1998;36:992-1002.
4. Wirsing v König CH, Finger H. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection. Eur J Clin Microbiol Infect Dis 1994; 13:455-458.
5. Novotny P. Pathogenesis in Bordetella species. J Infect Dis 1990; 161:581-582.
6. Arico B, Rappuoli R. Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol 1987; 169:2847-2853.
7. Khelef N, Danve B, Quentin-Millet M-J, Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immun 1993; 61:486-490.
8. He Q, Edelman K, Arvilommi H, Mertsola J. Protective role of immunoglobulin G antibodies to filamentous hemagglutinin and pertactin of Bordetella pertussis in Bordetella parapertussis infection. Eur J Clin Microbiol Infect Dis 1996; 15:793-798.
9. Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin, and pertactin in children with pertussis. Scand J Infect Dis 1995; 27:273-277.
10. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine Pediatrics 1998; 101:1-11.
11. Isacson J, Trollfors B, Taranger J, Zackrisson G, Lagergard T. How common is whooping cough in a nonvaccinating country? Pediatr Infect Dis J 1993; 12:284-288.
12. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med 1995; 333: 1045-1050.
13. Taranger J, Trollfors B. Lagergård T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997; 16:180-184.
14. WHO Meeting on Case Definitions of Pertussis, Geneva, Switzerland, January 10-11, 1991. Geneva: World Health Organization, 1991; Issue No. MIM/EPI/PERT/91.1.
15. Regan J, Lowe F. Enrichment medium for the isolation of Bordetella J Clin Microbiol 1977;6:303-309.
16. Houard S, Hackel C, Herzog A, Bollen A. Specific identification of Bordetella pertussis by the polymerase chain reaction. Res Microbiol 1989; 140:477-487.
17. van der Zee A, Agterberg C, van Agterveld M, Peeters M, Mooi FR. Characterization of IS1001, an insertion sequence element of Bordetella parapertussis. J Bacteriol 1993; 175:141-147
18. Reizenstein E, Hallander H-O. Blackwelder WC, Kühn I, Ljungman M, Möllby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995; 183:279-290.
19. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsater J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-355.
20. Kwantes W, Joynson DHM, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hygiene 1983; 90:149-158
21. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-348.
22. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 1998; 280:635-637
23. Kawai H, Aoyama T, Murase Y, Tamura C, Imaizumi A. A causal relationship between Bordetella pertussis and Bordetella parapertussis infections. Scand J Infect Dis 1996; 28:377-381.
24. Mertsola J Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland. Eur J Clin Microbiol 1985, 4:123-128
25. Taranger J, Trollfors B, Lagergård T, Zackrisson G. Parapertussis infection followed by pertussis infection Lancet 1994. 344:1703.